Varenicline in the treatment of tobacco dependence.

Neuropsychiatric Disease and Treatment
Karl Fagerström, John Hughes

Abstract

Varenicline, a partial agonist of alpha(4)beta(2) nicotinic acetylcholine receptors, is the most recently approved drug for smoking cessation. This paper reviews the outcomes of Phase 2 and Phase 3 clinical trials that assess the efficacy of varenicline in comparison to placebo and other smoking cessation pharmacotherapies, ie, sustained-release bupropion (bupropion SR) and nicotine transdermal patch. Varenicline has higher abstinence rates than placebo and the alternative active treatments at the end of standard regimen treatment periods. Significantly higher abstinence rates were also found with varenicline in comparison to both placebo and bupropion SR at the end of a 40-week non-treatment follow-up period. Varenicline typically tripled the abstinence rates compared with placebo. In addition, varenicline reduced craving and withdrawal symptoms as well as some of the positive experiences associated with smoking to a greater extent than placebo, bupropion SR, and nicotine replacement therapy (NRT). These findings are consistent with the proposed agonist/antagonist effects of varenicline. Preliminary studies assessing individual variables such as smoking dependency level and smoking reinforcement types provide justification to ...Continue Reading

References

Sep 1, 1991·British Journal of Addiction·T F HeathertonK O Fagerström
Apr 1, 1989·Journal of Behavioral Medicine·K O Fagerstrom, N G Schneider
Sep 1, 1994·The American Journal of Medicine·W TerresA Rosenberg
Oct 1, 1993·Journal of Consulting and Clinical Psychology·J E Henningfield, R M Keenan
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·N L Benowitz
Jul 17, 2001·Chemical Research in Toxicology·D HoffmannK El-Bayoumy
Jan 5, 2002·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·M R PicciottoJ P Changeux
May 2, 2002·Nature Medicine·Ann E Kelley
Jul 5, 2002·Respiration; International Review of Thoracic Diseases·N LindblomT H Svensson
May 15, 2003·Preventive Medicine·Mary Ellen WewersDonald R Shopland
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Julia A Critchley, Simon Capewell
Oct 28, 2003·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Ovide F PomerleauCynthia S Pomerleau
Jul 22, 2004·The Cochrane Database of Systematic Reviews·C SilagyG Fowler
Aug 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caroline CohenPhilippe Soubrié
Oct 21, 2004·The Cochrane Database of Systematic Reviews·J HughesT Lancaster
Apr 1, 2005·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Andrew HylandK Michael Cummings
Apr 2, 2005·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·David J K Balfour
May 13, 2005·Journal of Medicinal Chemistry·Jotham W CoeBrian T O'Neill
Oct 14, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R Scott ObachJotham W Coe
May 17, 2006·International Journal of Clinical Practice·J Foulds
Jun 22, 2006·American Journal of Health Behavior·Jonathan FouldsGeorge G Rhoads
Jul 6, 2006·JAMA : the Journal of the American Medical Association·David GonzalesUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Douglas E JorenbyUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Serena TonstadUNKNOWN Varenicline Phase 3 Study Group
Aug 16, 2006·Archives of Internal Medicine·Jean-François Etter
Oct 20, 2006·Journal of Clinical Pharmacology·Aaron H BursteinHélène M Faessel
Jan 11, 2007·Annual Review of Pharmacology and Toxicology·Eric C K Siu, Rachel F Tyndale
Mar 17, 2007·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·John R Hughes
Apr 5, 2007·Current Medical Research and Opinion·Kathryn E WilliamsJason Gong
Jun 19, 2007·Trends in Pharmacological Sciences·Hans RollemaKathryn E Williams
Apr 30, 2008·American Journal of Health Behavior·Mitchell NidesKathryn E Williams

❮ Previous
Next ❯

Citations

Oct 12, 2014·Current Cardiology Reports·Christopher Bullen
Jun 16, 2009·Biochemical Pharmacology·Linda P DwoskinMichael T Bardo
Jan 10, 2013·Drug and Alcohol Dependence·Lara A RayKaren Miotto
Nov 27, 2009·Journal of Psychopharmacology·Laura Mattioli, Marina Perfumi
Aug 2, 2014·Therapeutic Advances in Drug Safety·Yohalakshmi Chelladurai, Sonal Singh
Nov 9, 2010·Clinical Pharmacokinetics·Hélène M FaesselAaron H Burstein
Jun 9, 2010·Expert Review of Respiratory Medicine·Serena Tonstad, Hans Rollema
Sep 1, 2016·BMC Medical Research Methodology·Tianjiao Dai, Sanjay Shete
Feb 6, 2019·The Journal of General Physiology·Amol V ShivangeHenry A Lester
Aug 7, 2017·Internal Medicine Journal·Catherine J LucasJennifer H Martin
Aug 25, 2015·Current Addiction Reports·Darlene H BrunzellClaire I Dixon
Aug 2, 2008·Current Opinion in Cardiology·Andrew Pipe
Aug 13, 2013·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Melanie CanterberryMark S George
Apr 26, 2020·Cells·Ann Marie CentnerGloria Salazar
Dec 17, 2020·Panminerva Medica·Stefan C Stanel, Pilar Rivera-Ortega
Feb 5, 2015·ACS Chemical Neuroscience·Kerry L PriceSarah C R Lummis
Jan 7, 2022·Obstetrics and Gynecology·Marcela C Smid, Mishka Terplan

❮ Previous
Next ❯

Methods Mentioned

BETA
cognitive behavioral therapy
pharmacotherapy
pharmacotherapies

Software Mentioned

QSU

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved